Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8219167 | 0.89 | CHRNA7 (0.61) | CHRNA7OPRM1OPRD1OPRK1 | |
| Iodide SCHEMBL8221206 | 0.87 | CHRNA7 (0.59) | CHRNA7OPRM1OPRD1OPRK1 | |
| SCHEMBL3866433 | 0.87 | CHRNA7 (0.46) | CHRNA7OPRM1OPRD1OPRK1 | |
| SCHEMBL19406891 | 0.80 | CHRNA7 (0.46) | CHRNA7MTNR1BMTNR1A | |
| SCHEMBL6495737 | 0.76 | SLC6A2 (0.43) | CHRNA7MTNR1BMTNR1A | |
| SCHEMBL19398840 | 0.76 | MTNR1B (0.43) | CHRNA7MTNR1BMTNR1A | |
| SCHEMBL2060177 | 0.75 | FAAH (0.57) | OPRM1OPRK1 | |
| SCHEMBL4135489 | 0.75 | FAAH (0.57) | OPRM1OPRK1 | |
| SCHEMBL4141990 | 0.75 | FAAH (0.57) | OPRM1OPRK1 | |
| SCHEMBL5264779 | 0.75 | CHRNA7 (0.77) | CHRNA7OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919335-B2 | Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection | BRISTOL-MYERS SQUIBB CO. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | XDH, IMPDH1, IMPDH2 | CHRNA7 2605/4885OPRM1 1693/4885OPRD1 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.